Chemomab Therapeutics Ltd ADR Dossier
Qualitative Analysis
Business overview
Chemomab Therapeutics Ltd. (Nasdaq: CMMB) is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet needs. The company's lead product candidate is nebokitug (also known as CM-101), a first-in-class humanized monoclonal antibody designed to bind and neutralize the soluble protein CCL24. CCL24 is a key driver of the biological pathways that promote liver, skin, and lung fibrosis and inflammation. Chemomab is primarily targeting rare indications, specifically primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Laying the groundwork and finalizing the regulatory and operational path for the Phase 3 clinical trial of nebokitug (CM-101) in primary sclerosing cholangitis (PSC). The trial design is aligned with the FDA as a single, event-driven registration study of approximately 350 patients that does not require liver biopsies.
Expected impact: Positions nebokitug to potentially become the first approved disease-modifying therapy for PSC.
Actively progressing discussions and evaluating potential strategic collaborations, licensing opportunities, or partnerships with larger biopharmaceutical companies to optimize development resources and accelerate the Phase 3 launch of nebokitug.
Expected impact: Extends cash runway, reduces dilution risk, and provides commercialization capabilities.
Implementing cost-control measures across the organization, including the temporary suspension of the Phase 2-ready systemic sclerosis trial, to prioritize resources on the high-impact PSC program and extend the cash runway.
Expected impact: Extended the cash runway through the first quarter of 2027 (as of Q1 2026 updates).
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Critical for ensuring the quality, consistency, and regulatory compliance of the drug supply of nebokitug for late-stage clinical development and eventual commercialization, with CMC strategies fully aligned with the FDA.
Terms: Not publicly disclosed.